Islet cell and glutamic acid decarboxylase antibodies present at diagnosis of diabetes predict the need for insulin treatment. A cohort study in young adults whose disease was initially labeled as type 2 or unclassifiable diabetes.
OBJECTIVE
To clarify the predictive value of islet cell antibody (ICA) and GAD65 antibody (GADA) present at diagnosis with respect to the need for insulin treatment 6 years after diagnosis in young adults initially considered to have type 2 or unclassifiable diabetes.


METHODS
The patient material was representative of the entire Swedish population, consisting of patients who were 15-34 years old at diagnosis of diabetes in 1987-1988 but were not considered to have type 1 diabetes at onset. At follow-up, 6 years after the diagnosis, it was noted whether the patient was treated with insulin. The presence of ICA was determined by an immunofluorescence assay, and GADAs were measured by a radioligand assay.


RESULTS
Six years after diagnosis, 70 of 97 patients were treated with insulin, and 27 of 97 patients were treated with oral drugs or diet alone. At diagnosis, ICAs and GADAs were present in 41 (59%) of 70 patients and 41 (60%) of 68 patients, respectively, of those now treated with insulin, compared with only 1 (4%) of 26 patients and 2 (7%) of 27 patients who were still not treated with insulin. For either ICA or GADA, the corresponding frequencies were 50 (74%) of 68 for patients who were later treated with insulin and 3 (12%) of 26 for those who were still not treated with insulin, respectively. The sensitivity for later insulin treatment was highest (74%) for the presence of ICA or GADA, and the specificity was highest (100%) for ICA and GADA. The positive predictive value was 100% for the combination of ICA and GADA, 98% for ICA alone, and approximately 95% for GADA alone.


CONCLUSIONS
Determination of the presence of ICA and GADA at diagnosis of diabetes improves the classification of diabetes and predicts the future need of insulin in young adults.
Littorin
B
B
Department of Community Health Sciences, University of Malmö/Lund, Sweden.
Sundkvist
G
G
Hagopian
W
W
Landin-Olsson
M
M
Lernmark
A
A
Ostman
J
J
Arnqvist
H J
HJ
Blohmé
G
G
Bolinder
J
J
Eriksson
J W
JW
Lithner
F
F
Scherstén
B
B
Wibell
L
L
D000328:Adult; D000906:Antibodies / Q000032:analysis*; D001323:Autoantibodies / Q000032:analysis*; D015331:Cohort Studies; D003920:Diabetes Mellitus / Q000145:classification / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology*; D003924:Diabetes Mellitus, Type 2 / Q000175:diagnosis; D003937:Diagnosis, Differential; D005260:Female; D005500:Follow-Up Studies; D005544:Forecasting; D005968:Glutamate Decarboxylase / Q000276:immunology*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007328:Insulin / Q000627:therapeutic use*; D008297:Male
D000906:Antibodies; D001323:Autoantibodies; D007004:Hypoglycemic Agents; D007328:Insulin; C024211:islet cell antibody; D005968:Glutamate Decarboxylase